Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL250 Target Snapshot

Platelet-activating factor receptor · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
1,453Compounds
117Assays
4Approved Drugs
2,175.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Platelet-activating factor receptor shows approved-linked disease relevance led by allergic disease. 4 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P25105. Start with allergic disease, then reuse UniProt P25105 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with allergic disease, then reuse UniProt P25105 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14 1 linked drug
Open source guide
Disease program
allergic disease

Platelet-activating factor receptor shows approved-linked disease relevance led by allergic disease. 4 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.

Start review with allergic disease because it currently carries approved-linked support. Linked drugs include RUPATADINE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Platelet-activating factor receptor as ChEMBL target CHEMBL250, mapped to UniProt P25105. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Platelet-activating factor receptor
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL250
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
P25105
Platelet-activating factor receptor
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Platelet-activating factor receptor is the right protein anchor across sources, using UniProt P25105 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why allergic disease is currently framed as approved-linked support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NamePlatelet-activating factor receptor
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtP25105
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelPlatelet-activating factor receptor
UniProt AccessionP25105
Component TypeProtein
Sequence Length342 aa

Platelet-activating factor receptor

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Platelet-activating factor receptor, mapped to UniProt P25105. Sequence length is 342 aa.

Mapped IDP25105
Review namePlatelet-activating factor receptor
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Platelet-activating factor receptor shows approved-linked disease relevance led by allergic disease. 4 more disease programs remain visible in the same review block.

Approved-linked Approved
allergic disease
1 linked drug · 1 direct · 1 efficacy
Linked drugRUPATADINE
Late clinical Phase III
rheumatoid arthritis
1 linked drug · 1 direct · 1 efficacy
Linked drugRUPATADINE
Late clinical Phase III
urticaria
1 linked drug · 1 direct · 1 efficacy
Linked drugRUPATADINE
Clinical signal Phase II
cold urticaria
1 linked drug · 1 direct · 1 efficacy
Linked drugRUPATADINE
Clinical signal Phase II
Mastocytosis
1 linked drug · 1 direct · 1 efficacy
Linked drugRUPATADINE
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with allergic disease because it currently carries approved-linked support. Linked drugs include RUPATADINE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseallergic disease
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

4
Approved
7
Phase II
Assay Mix

Activity Type Distribution

IC501,305.0
KI869.0
KD1.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL157078 10.82 IC50 0.015 Preclinical
CHEMBL1235246 9.82 Ki 0.15 Preclinical
CHEMBL277701 9.7 IC50 0.2 Preclinical
CHEMBL1235246 9.55 IC50 0.28 Preclinical
CHEMBL20195 9.52 IC50 0.3 Preclinical
CHEMBL322832 9.42 Ki 0.38 Clinical
CHEMBL5408810 9.4 IC50 0.4 Preclinical
CHEMBL5439289 9.4 IC50 0.4 Preclinical
CHEMBL5411872 9.3 IC50 0.5 Preclinical
CHEMBL5433867 9.3 IC50 0.5 Preclinical
Distribution

pChEMBL Value Distribution

27
5.0
40
5.5
72
6.0
70
6.5
71
7.0
63
7.5
59
8.0
20
8.5
21
9.0
4
9.5
pChEMBL
Approved Drugs

Approved Drugs

BROTIZOLAM
CHEMBL32479
Approved 1984
Properties Compare Identifier
Assay Landscape

Assay Landscape

117
Total Assays
384
Tested Compounds
2
Assay Types
Binding — 99 assays, 384 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 56 379 7.0
single protein format 40 2 6.1
cell-based format 2 1 8.0
tissue-based format 1 2 5.1
Functional — 18 assays, 55 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 5 12 9.2
organism-based format 5 0 —
assay format 4 24 7.2
cell-free format 2 19 5.7
tissue-based format 2 0 —

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine